RxDoctor Payments Data

Aaron Florkowski, MD

Ophthalmology · Shawnee, KSNPI 1326013251

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Alcon at 50.9% of the total.

$3,288in general payments, 2019–2025

Across 91 payments — averaging $36.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$431
  • Carl Zeiss Meditec USA, Inc.$210
  • Johnson & Johnson Surgical Vision, Inc.$205
  • Tarsus Pharmaceuticals, Inc.$187
  • Rayner Intraocular Lenses Limited$183
  • plus $396 from 11 others

What the payments were for

  • Food & beverage$3,26299%
  • Entertainment$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,288 in reported general payments places this provider in the 75th percentile of 135 ophthalmology providers in Kansas.

See all ophthalmology providers in Kansas

Medicare billing

Part B allowed, 2024
$243,124
Medicare patients
512
Services billed
1,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine23$21,004
ProlensaBromfenac Sodium50$17,102
LumiganBimatoprost15$9,072
CombiganBrimonidine Tartrate/Timolol25$7,950
Prednisolone Acetate317$7,901
Bromfenac Sodium27$4,865
Latanoprost329$4,732
IlevroNepafenac13$4,612
Ofloxacin244$2,686
Ketorolac Tromethamine155$2,627
Brimonidine Tartrate36$2,484
Travoprost22$1,896
Loteprednol Etabonate11$1,392
Timolol Maleate153$1,231
Dorzolamide Hcl26$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$431$38,02763 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$98$18,49561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 135 ophthalmology providers in Kansas.

Other ophthalmology in Shawnee

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →